DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vbh5ff/triple_analysis) has announced the addition of the "Triple Analysis: Melanoma, Apoptosis and Antibodies" report to their offering.
This report focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Synopsis
Part I: Melanoma
based on the publication: Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
Part II: Apoptosis
based on the publication: Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
Part III: Antibodies
based on the publication: Cancer Antibodies: Drug Target Atlas and Competitive Outlook
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
For more information visit http://www.researchandmarkets.com/research/vbh5ff/triple_analysis
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
